Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.

Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301. doi: 10.1007/s00280-019-03960-w. Epub 2019 Sep 23.

PMID:
31549216
2.

Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.

Schvartsman G, Ma J, Bassett RL Jr, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC.

Cancer. 2019 Dec 1;125(23):4193-4202. doi: 10.1002/cncr.32454. Epub 2019 Aug 9.

PMID:
31398264
3.

Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.

Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P.

Clin Cancer Res. 2019 Nov 1;25(21):6406-6416. doi: 10.1158/1078-0432.CCR-19-1259. Epub 2019 Aug 1.

PMID:
31371342
4.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
5.

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.

Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P.

Nat Med. 2019 Jun;25(6):929-935. doi: 10.1038/s41591-019-0474-7. Epub 2019 Jun 6.

PMID:
31171876
6.

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

Ascierto PA, Bruzzi P, Eggermont A, Hamid O, Tawbi HA, van Akkooi A, Testori A, Caracò C, Puzanov I, Perrone F.

J Transl Med. 2019 May 10;17(1):148. doi: 10.1186/s12967-019-1892-5.

7.

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

Butterfield LH, Vujanovic L, Santos PM, Maurer DM, Gambotto A, Lohr J, Li C, Waldman J, Chandran U, Lin Y, Lin H, Tawbi HA, Tarhini AA, Kirkwood JM.

J Immunother Cancer. 2019 Apr 24;7(1):113. doi: 10.1186/s40425-019-0552-x.

8.

Reply to A. Shinde et al.

Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, Goldberg SB, Chiang VL.

J Clin Oncol. 2019 Apr 20;37(12):1031-1032. doi: 10.1200/JCO.18.02463. Epub 2019 Feb 26. No abstract available.

PMID:
30807233
9.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA.

Cancer Discov. 2019 May;9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20.

10.

Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Chung C, Margolin K.

N Engl J Med. 2018 Nov 29;379(22):2178. doi: 10.1056/NEJMc1812500. No abstract available.

PMID:
30485776
11.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
12.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
13.

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM.

J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632. [Epub ahead of print]

PMID:
30359157
14.

NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.

Tarhini AA, Frankel P, Ruel C, Ernstoff MS, Kuzel TM, Logan TF, Khushalani NI, Tawbi HA, Margolin KA, Awasthi S, Butterfield LH, McDermott D, Chen A, Lara PN, Kirkwood JM.

Cancer. 2018 Nov 15;124(22):4332-4341. doi: 10.1002/cncr.31734. Epub 2018 Oct 10.

15.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

16.

New Era in the Management of Melanoma Brain Metastases.

Tawbi HA, Boutros C, Kok D, Robert C, McArthur G.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:741-750. doi: 10.1200/EDBK_200819. Review.

PMID:
30231345
17.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

18.

Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!

Keung EZ, Tawbi HA.

Cancer Discov. 2018 Aug;8(8):914-917. doi: 10.1158/2159-8290.CD-18-0618.

19.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT.

JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22.

20.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
21.

PD-1 inhibition in sarcoma still needs investigation - Authors' reply.

Tawbi HA, Bolejack V, Burgess M, Schuetze S.

Lancet Oncol. 2018 Jan;19(1):e7. doi: 10.1016/S1470-2045(17)30922-1. No abstract available.

PMID:
29304367
22.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Erratum in: Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
23.

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.

Davar D, Ding F, Saul M, Sander C, Tarhini AA, Kirkwood JM, Tawbi HA.

J Immunother Cancer. 2017 Sep 19;5(1):74. doi: 10.1186/s40425-017-0279-5.

24.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Schuetze SM, Bolejack V, Choy E, Ganjoo KN, Staddon AP, Chow WA, Tawbi HA, Samuels BL, Patel SR, von Mehren M, D'Amato G, Leu KM, Loeb DM, Forscher CA, Milhem MM, Rushing DA, Lucas DR, Chugh R, Reinke DK, Baker LH.

Cancer. 2017 Jan 1;123(1):90-97. doi: 10.1002/cncr.30379. Epub 2016 Oct 3.

25.

SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.

Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, Tawbi HA, Rushing DA, Patel SR, Thomas DG, Chugh R, Reinke DK, Baker LH.

Cancer. 2016 Mar 15;122(6):868-74. doi: 10.1002/cncr.29858. Epub 2015 Dec 28.

26.

Retinal imaging with en face and cross-sectional optical coherence tomography delineates outer retinal changes in cancer-associated retinopathy secondary to Merkel cell carcinoma.

Mesiwala NK, Shemonski N, Sandrian MG, Shelton R, Ishikawa H, Tawbi HA, Schuman JS, Boppart SA, Labriola LT.

J Ophthalmic Inflamm Infect. 2015 Dec;5(1):53. doi: 10.1186/s12348-015-0053-0. Epub 2015 Aug 19.

27.

MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.

Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty KT, Lee SJ, Wilson MA, Nathanson KL, Benos PV, Tawbi HA.

Clin Epigenetics. 2015 Jun 4;7:58. doi: 10.1186/s13148-015-0092-2. eCollection 2015.

28.

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.

Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA.

Br J Cancer. 2015 May 12;112(10):1644-51. doi: 10.1038/bjc.2015.126. Epub 2015 Apr 21.

29.

A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.

Shou Y, Robinson DM, Amakye DD, Rose KL, Cho YJ, Ligon KL, Sharp T, Haider AS, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley DM, Hargrave DR, Casanova M, Tawbi HA, Rodon J, Thomas AL, Mita AC, MacDonald TJ, Kieran MW.

Clin Cancer Res. 2015 Feb 1;21(3):585-93. doi: 10.1158/1078-0432.CCR-13-1711. Epub 2014 Dec 3.

30.

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC.

Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12.

31.

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM.

Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.

32.

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.

Tawbi HA, Tran AL, Christner SM, Lin Y, Johnson M, Mowrey E, Appleman LR, Stoller R, Miller BM, Egorin MJ, Beumer JH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1143-7. doi: 10.1007/s00280-013-2283-x. Epub 2013 Sep 14.

33.

Melanoma brain metastases: an unmet challenge in the era of active therapy.

Gorantla V, Kirkwood JM, Tawbi HA.

Curr Oncol Rep. 2013 Oct;15(5):483-91. doi: 10.1007/s11912-013-0335-3. Review.

34.

Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.

Tawbi HA, Beumer JH, Tarhini AA, Moschos S, Buch SC, Egorin MJ, Lin Y, Christner S, Kirkwood JM.

Ann Oncol. 2013 Apr;24(4):1112-9. doi: 10.1093/annonc/mds591. Epub 2012 Nov 21.

35.

Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.

Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS.

Crit Care. 2012 Aug 31;16(4):231. doi: 10.1186/cc11304. Review.

36.

Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect.

Tawbi HA, Kirkwood JM.

Nat Rev Clin Oncol. 2012 Sep;9(9):496-7. doi: 10.1038/nrclinonc.2012.138. Epub 2012 Aug 14. No abstract available.

PMID:
22889973
37.

A potential role for nilotinib in KIT-mutated melanoma.

Tran A, Tawbi HA.

Expert Opin Investig Drugs. 2012 Jun;21(6):861-9. doi: 10.1517/13543784.2012.679341. Epub 2012 Apr 16. Review.

PMID:
22500535
38.

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.

Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C, Kirkwood JM.

J Clin Oncol. 2012 Jan 20;30(3):322-8. doi: 10.1200/JCO.2011.37.5394. Epub 2011 Dec 19. Erratum in: J Clin Oncol. 2012 Nov 1;30(31):3903.

39.

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.

Tawbi HA, Villaruz L, Tarhini A, Moschos S, Sulecki M, Viverette F, Shipe-Spotloe J, Radkowski R, Kirkwood JM.

Br J Cancer. 2011 Sep 6;105(6):773-7. doi: 10.1038/bjc.2011.285. Epub 2011 Aug 2.

40.

Chemotherapy resistance abrogation in metastatic melanoma.

Tawbi HA, Buch SC.

Clin Adv Hematol Oncol. 2010 Apr;8(4):259-66. Review.

PMID:
20505649
41.

Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?

Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ.

Nat Clin Pract Oncol. 2009 Feb;6(2):70-1. doi: 10.1038/ncponc1297. Epub 2008 Dec 17.

PMID:
19092800
42.

Management of metastatic melanoma.

Tawbi HA, Kirkwood JM.

Semin Oncol. 2007 Dec;34(6):532-45. Review.

PMID:
18083377
43.

Calcitonin in the treatment of transient osteoporosis of the hip.

Arayssi TK, Tawbi HA, Usta IM, Hourani MH.

Semin Arthritis Rheum. 2003 Jun;32(6):388-97. Review.

PMID:
12833247

Supplemental Content

Loading ...
Support Center